Literature DB >> 34114731

Use of oxidised regenerated cellulose/collagen dressings versus standard of care over multiple wound types: A systematic review and meta-analysis.

Saeed A Chowdhry1, Yeni Nieves-Malloure2, Mark Camardo2, Julie M Robertson2, Joshua Keys2.   

Abstract

Oxidised regenerated cellulose (ORC)/collagen dressings help maintain physiologically moist wound environments conducive to wound healing. While evidence supporting ORC/collagen dressing use exists, comprehensive assessment is needed. This systematic review/meta-analysis evaluated the performance of ORC/collagen dressings compared with standard dressings. A systematic literature search was performed using PUBMED, EMBASE, and QUOSA Virtual Library. Published studies and conference abstracts were assessed between 1 January 1996 and 27 July 2020. Comparative studies in English completed by 31 December 2019, with a study population ≥10 were included. Patient demographics, wound healing, and protease concentrations were extracted. A random-effect model was used to assess the effect of ORC/collagen dressings. Twenty studies were included following removal of duplicates and articles not meeting inclusion criteria. A statistically significant effect in favour of ORC/collagen dressings was found for wound closure (P = 0.027) and percent wound area reduction (P = 0.006). Inconclusive evidence or limited reporting prevented assessment of time to complete healing, days of therapy, number of dressing applications, pain, matrix metalloproteinase, elastase, plasmin, and gelatinase concentration. Statistically significant increase in wound closure rates and percent wound area reduction were observed in patients receiving ORC/collagen dressings compared with standard dressings in this systematic review/meta-analysis.
© 2021 The Authors. International Wound Journal published by Medicalhelplines.com Inc (3M) and John Wiley & Sons Ltd.

Entities:  

Keywords:  cellulose dressings; collagen dressings; matrix metalloproteinases; meta-analysis; wound healing

Mesh:

Substances:

Year:  2021        PMID: 34114731      PMCID: PMC8762558          DOI: 10.1111/iwj.13625

Source DB:  PubMed          Journal:  Int Wound J        ISSN: 1742-4801            Impact factor:   3.315


INTRODUCTION

Rates of chronic and complex wounds have been increasing, leading to the development of advanced wound dressings targeting the wound environment and helping remove potential barriers to healing, such as inadequate moisture and increased concentrations of proteases. , One such dressing family, oxidised regenerated cellulose (ORC)/collagen dressings, has a growing body of published literature to support its use. Increased wound healing rates and reduced protease activity in the wound bed have been reported in a wide variety of patients receiving ORC/collagen dressings. , , , , , Although much of the available literature seems to be small case series without comparative dressing groups, there are a handful of comparative studies, including randomised controlled trials, that have been published. As such, a more comprehensive assessment of ORC/collagen dressing use in these comparative studies is needed. This systematic review/meta‐analysis identified a set of comparative studies that evaluated the performance of ORC/collagen dressings compared with standard dressings in patients with all wound types. Differences in wound area reduction, percent area reduction, wound closure rates, and concentrations of matrix metalloproteainase‐2 (MMP‐2), elastase, plasmin, and gelatinase were assessed.

METHODS

This systematic review/meta‐analysis conformed to the statement and reporting check list of the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses. The systematic literature review and meta‐analysis was conducted using an internal, unpublished protocol to evaluate the performance of ORC/collagen dressings (3M™ Promogran™ Matrix Wound Dressing, and 3M™ Promogran Prisma™ Matrix, Systagenix Wound Management Ltd, Gargrave, UK) versus standard dressings (ie, gauze, film dressings, hydrocolloid dressings, alginate dressings, or silicone dressings).

Literature search

A systematic literature search using PubMed, EMBASE, and QUOSA Virtual Library was performed on 27 July 2020. Literature between 1 January 1996 and 27 July 2020 were assessed. The following search terms were used: “Promogran” OR “ORC/Collagen” OR “ORC/collagen/silver‐ORC” OR (“oxidized regenerated cellulose AND Collagen”), OR (“kinetic concepts” OR “systagenix”) AND (“ORC/Collagen” OR “ORC/collagen/silver‐ORC” OR “oxidized regenerated cellulose” AND “Collagen.” Study inclusion criteria were published studies and conference abstracts written in English, comparison of ORC/dressings over any wound type to standard of care, and endpoint/outcomes of: healing rate, actual or percentage of wound area reduction, number and/or percentage of wounds healed, time to complete healing, MMP‐2, elastase, plasmin, gelatinase concentration, wound scores, and pain scores. Studies conducted through 31 December 2019 and study populations ≥10 were also included in the analysis. Meta‐analyses, reviews, protocols, pre‐clinical studies, veterinary studies, and studies with <10 patients were excluded. Studies were selected for inclusion following a review of titles and abstracts to identify studies for further review. Full text articles were assessed for eligibility by two independent reviewers. A third person reviewed the article when a disagreement occurred. Data extraction was completed by one reviewer and was checked by a second independent reviewer. Disagreements were resolved by discussion between the two reviewers, or a third reviewer was brought in for review and discussion. Extracted data included funding source, evidence level, bias assessments, study date range, wound type, number of patients enrolled, number of patients analysed, standard of care treatment, patient characteristics and comorbidities, differences in baseline characteristics, healing rate, wound area reduction, number and/or percentage of wounds healed or closed, time to complete healing, number of dressing changes/applications, total days of therapy, adverse events, haemostasis, wound scores, pain scores, and MMP‐2, elastase, plasmin, and gelatinase concentration. All studies included in the meta‐analysis were assessed for bias in selection (randomisation and allocation concealment), performance (blinding of participants and personnel and outcome assessments), attrition (lost to follow‐up or incomplete outcome data), and reporting (comparison of reported results to endpoints defined in the protocol). The Cochrane Collaboration tool for assessing risk of bias using the low risk, high risk, or unclear designations was used.

Statistical analysis

The meta‐analyses were performed by calculating standardised mean difference using random‐effect models to assess the effect of ORC/collagen dressings versus the standard dressings on area reduction in cm2. For percentage of wounds closed, odds ratios (ORs) were calculated using a random‐effect model. Weighted standardised mean difference and 95% confidence intervals (CIs) were calculated to pool ORC/collagen and standard dressing groups in each publication for analysis. The outcomes were measured using a continuous variable. Treatment effects for each study were combined, and a random effects model was used for each analysis performed. The chi‐square test of independence was used to assess heterogeneity. However, regardless of the heterogeneity assessment, the more conservative random effect models for sensitivity analyses were used. All analyses were performed using Comprehensive Meta‐Analysis Version 3.3.070 software (Biostat Inc, Englewood, New Jersey). Funnel plots were used to assess selection, identification, and publication bias displaying the OR by the standard error of each study. Descriptive graphs were created for MMP‐2, elastase, plasmin, and gelatinase concentrations.

RESULTS

Literature search results

A total of 559 publications were identified during the literature search. After removal of duplicate publications (n = 134), 425 abstracts and titles were screened against the inclusion and exclusion criteria. Reasons for study exclusion are list in Figure 1. After the completion of the screening process, a total of 20 comparative studies representing 2893 patients, of which 1867 (64.5%) received ORC collagen dressings and 1026 (35.5%) received standard dressings, were included in the meta‐analysis (Figure 1). , , , , , , , , , , , , , , , , , , ,
FIGURE 1

PRISMA flowchart showing the literature search process. ORC, Oxidised regenerated cellulose

PRISMA flowchart showing the literature search process. ORC, Oxidised regenerated cellulose

Description of studies

Study characteristics of the included abstracts and articles are listed in Table 1. Eleven randomised controlled trials, , , , , , , , , , , five prospective cohorts, , , , , one case–control study, and three retrospective cohorts , , were included in the meta‐analysis. The most common wound types reported were diabetic foot ulcers and venous leg ulcers. However, Snyder et al was not restricted to wound type and reported results on a wide variety of lower extremity wounds. Eight studies reported patient risk factors for impaired wound healing including diabetes, peripheral vascular disease, and hypertension. , , , , , , Dressings used in the control group included gauze, dermal templates, foam hydropolymer dressings, soft silicone contact layers, hydrocolloid dressings, film dressings, and non‐adherent petrolatum‐impregnated dressings. Length of treatment was reported for five studies with a treatment range from 8 to 56 days for both ORC/collagen and control dressing groups. , , , , Limited reporting on time to complete healing, number of dressing changes and applications, total days of therapy, wound scores, and pain scores prevented further assessment of these outcomes.
TABLE 1

Characteristics of studies included in the meta‐analysis

StudyStudy typeWound typeNumber of patientsPopulation risk factorsTherapy usedLength of therapy (days, SD)
TreatmentControlTreatmentControl
Ambrosch 2006 11 PCChronic ulcers25Not reportedORC/collagenSOC10‐1410‐14
Catalfamo 2013 12 PCOral cavity wounds80Not reportedORC/collagenGauze, hydrogen peroxide, iodopovidoneNRNR
Chowdhry 2019 13 RCDonor site wounds59HTN, hyperlipidaemia, PVD, Obesity, COPD, CHF, CAD, asthma, atrial fibrillationORC/Collagen/Ag‐ORCFilm dressingNRNR
Cullen 2017 14 RCTVLU49Not reportedORC/collagen/Ag‐ORCSOCNRNR
Gottrup 2013 15 RCTDFU39DiabetesORC/collagen/Ag‐ORCSOCNRNR
Griffin 2019 16 RCDFU844Arterial vascular disease, HTN, PVD, endovascular treatmentORC/Collagen/Ag‐ORCECM; endoform natural dermal template21 (NR)21 (NR)
Kakagia 2007 17 RCTDFU34Not reportedORC/collagenGravitational platelet separation system56 (NR)56 (NR)
Kloeters 2015 18 RCTPI33Not reportedORC/collagenFoam hydropolymer dressingNRNR
Lazaro‐Martinez 2007 19 RCTDFU38HTN, heart disease, PVD, amputationORC/collagenSOC14 (NR)14 (NR)
Lobmann 2006 20 PCDFU33Not reportedORC/collagen/Ag‐ORCSOC8 (NR)8 (NR)
Lüedemann 2009 21 PCDFU21Not reportedORC/collagenSOCNRNR
Motzkau 2011 22 RCTDFU19DiabetesORC/collagenSilicone wound contact layerNRNR
Nisi 2005 23 RCTPI80Not reportedORC/collagenDaily disinfection of the wound, gauze soaked in white Vaseline, and hydropolymer patchNRNR
Schmutz 2008 24 RCTVLU117Diabetes, vein thrombosisORC/collagenNano‐oligosaccharide factorNRNR
Smeets 2008 25 RCTVLU27Not reportedORC/collagenHydrocolloid dressingNRNR
Snyder 2010 26 RCPI, DFU, surgical wounds, VLUs, infected wounds, trauma974Not reportedORC/collagenGauze and saline38.6 (4.62)NR
Ulrich 2011 27 PCDFU32DiabetesORC/collagenHydrocolloid dressingNRNR
Veves 2002 28 RCTDFU276Not reportedORC/collagenMoistened gauzeNRNR
Vin 2002 29 RCTVLU73Hip arthrosis, knee arthrosis, diabetes, CHD, HTNORC/collagenNon‐adherent silicone dressing65.9 (23.9)63.8 (25.2)
Wollina 2005 30 CCVLU40Not reportedORC/collagenHydropolymer and hydrocolloid dressingsNRNR

Abbreviations: Ag, silver; CAD, coronary artery disease; CC, case–control study; CHD, coronary heart disease; CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; DFU, diabetic foot ulcer; HTN, hypertension; NR, not reported; ORC, oxidised regenerated cellulose; PC, prospective cohort; PI, pressure injury; PVD, peripheral vascular disease; RC, retrospective cohort; RCT, randomised controlled trial; SD, standard deviation; VLU, venous leg ulcer.

Characteristics of studies included in the meta‐analysis Abbreviations: Ag, silver; CAD, coronary artery disease; CC, case–control study; CHD, coronary heart disease; CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; DFU, diabetic foot ulcer; HTN, hypertension; NR, not reported; ORC, oxidised regenerated cellulose; PC, prospective cohort; PI, pressure injury; PVD, peripheral vascular disease; RC, retrospective cohort; RCT, randomised controlled trial; SD, standard deviation; VLU, venous leg ulcer.

Risk of bias

The randomisation method was adequately explained in 11 studies (Table 2). , , , , , , , , , , However, allocation masking was unclear in all 20 studies. Blinding of participants and personnel was considered high risk for all studies except Gottrup et al, where the participants and study personnel were blinded to treatment until the study had ended. Blinded outcomes assessments were high risk for 13 studies and unclear in seven studies (Table 2). All 20 studies were at low risk for selective reporting bias.
TABLE 2

Risk of bias within studies

StudyEvidence levelRandomisationAllocation maskingBlindingBlinded outcomes assessmentsEnrolled patients to number assessedResults to defined endpoints
Ambrosch 20062High riskUnclearHigh riskHigh riskLow riskLow risk
Catalfamo 20132High riskUnclearHigh riskUnclearLow riskLow risk
Chowdhry 20193High riskUnclearHigh riskHigh riskLow riskLow risk
Cullen 20171Low riskUnclearHigh riskHigh riskLow riskLow risk
Gottrup 20131Low riskLow riskHigh riskHigh riskLow riskLow risk
Griffin 20193High riskUnclearHigh riskHigh riskLow riskLow risk
Kakagia 20071Low riskUnclearHigh riskHigh riskLow riskLow risk
Kloeters 20151Low riskUnclearHigh riskHigh riskLow riskLow risk
Lazaro‐Martinez 20071Low riskUnclearHigh riskHigh riskLow riskLow risk
Lobmann 20062High riskUnclearHigh riskUnclearLow riskLow risk
Luedemann 20092High riskUnclearHigh riskUnclearLow riskLow risk
Motzkau 20111Low riskUnclearHigh riskUnclearLow riskLow risk
Nisi 20051Low riskUnclearHigh riskUnclearLow riskLow risk
Schmutz 20081Low riskUnclearHigh riskHigh riskLow riskLow risk
Smeets 20081Low riskUnclearHigh riskUnclearLow riskLow risk
Snyder 20103High riskUnclearHigh riskUnclearLow riskLow risk
Ulrich 20112UnclearUnclearHigh riskHigh riskLow riskLow risk
Veves 20021Low riskUnclearHigh riskHigh riskLow riskLow risk
Vin 20021Low riskUnclearHigh riskHigh riskLow riskLow risk
Wollina 20052High riskUnclearHigh riskHigh riskLow riskLow risk
Risk of bias within studies Because of differences in reporting, not all of the studies reported on all the assessed outcomes. Thus, the outcome with the highest number of reporting studies was used to assess the potential for publication bias. The funnel plot of odds ratio from wound closure implies that there is little publication bias in our analysis (Figure 2). The markers that lie outside of the confidence interval depict the heterogeneity of the studies in the analysis. This heterogeneity has been controlled in the meta‐analyses by utilising a random effects model.
FIGURE 2

Funnel plot of studies included in the meta‐analysis. Each circle indicates a single study; solid lines indicate the 95% confidence interval

Funnel plot of studies included in the meta‐analysis. Each circle indicates a single study; solid lines indicate the 95% confidence interval

Proportion of wounds closed

Wound healing was assessed during each study's follow‐up time ranging from 2 weeks to 6 months. Wounds receiving ORC/collagen dressings were 3.4 times more likely to close than wounds receiving control dressings (OR = 3.4, 95% CI [1.15, 10.1], P = 0.027; Figure 3). The Catalfamo et al study reported wound closures in all wounds for both treatment groups; therefore, an OR was unable to be calculated and the study could not be included in the analysis.
FIGURE 3

Forest plot of proportion of wounds closed comparing ORC/collagen dressings and standard dressing use. Each study is displayed with the standard difference of the means and standard error and 95% confidence interval

Forest plot of proportion of wounds closed comparing ORC/collagen dressings and standard dressing use. Each study is displayed with the standard difference of the means and standard error and 95% confidence interval

Percent area reduction

Using a random effects model, patients in the ORC/collagen group showed a greater percent area reduction compared with the control group (effect estimate of standard mean difference = 1.11, 95% CI [0.32, 1.90], P = 0.006; Figure 4). Studies that did not report standard deviations were not included in the analysis. An I 2 value of 0% was obtained indicating that the random effects model was successful in controlling for study variation.
FIGURE 4

Forest plot of percent area reduction comparing oxidised regenerated cellulose (ORC)/collagen dressings and standard dressing use. Each study is displayed with the standard difference of the means and standard error, and 95% confidence interval

Forest plot of percent area reduction comparing oxidised regenerated cellulose (ORC)/collagen dressings and standard dressing use. Each study is displayed with the standard difference of the means and standard error, and 95% confidence interval

Area reduction

Area of reduction was only assessed in two studies because of lack of reporting in the remaining 18 studies. The random effects analysis indicated that patients receiving ORC/collagen showed increased area reduction compared with patients receiving control dressings (effect estimate of standard mean difference = 0.61, 95% CI [0.11, 1.11], P = 0.017; Figure 5). An I 2 value of 0% demonstrates that the random effects model was successful in controlling for study variation.
FIGURE 5

Forest plot of area reduction comparing ORC/collagen dressing and standard dressing use. Each study is displayed with the standard difference of the means and standard error

Forest plot of area reduction comparing ORC/collagen dressing and standard dressing use. Each study is displayed with the standard difference of the means and standard error

MMP‐2 concentrations

Four studies reported MMP‐2 concentrations (Figure 6). , , , The studies assessed MMP‐2 concentrations at different time points and reported different concentration units; therefore, a meta‐analysis was unable to be performed. Lobmann et al, Motzkau et al, and Smeets et al did not find any statistically significant differences in MMP‐2 concentrations at any time point between ORC/collagen and control groups. , , However, Ulrich et al found significantly lower concentrations of MMP‐2 at day 5 in the ORC/collagen group.
FIGURE 6

Estimated MMP‐2 concentrations by study. MMP‐2 concentrations reported as ng/mL (A) and pg/mL/mg (B) are shown. Oxidised regenerated cellulose (ORC)/collagen group is represented by black bars and the control group is represented by white bars. *P‐value <0.05

Estimated MMP‐2 concentrations by study. MMP‐2 concentrations reported as ng/mL (A) and pg/mL/mg (B) are shown. Oxidised regenerated cellulose (ORC)/collagen group is represented by black bars and the control group is represented by white bars. *P‐value <0.05

Elastase concentrations

Three studies reported average elastase levels (Figure 7). , , Kloeters et al and Smeets et al observed a reduction in elastase concentrations in the ORC/collagen group compared across all time points. , Ulrich et al observed significant reduction in elastase concentration on day 5, 14, 28, 42, and 56 in the ORC/collagen group. A meta‐analysis could not be performed because of the elastase levels being estimated from graphical presentations.
FIGURE 7

Estimated elastase concentrations by study. Oxidised regenerated cellulose (ORC)/collagen group is represented by black bars and the control group is represented by white bars. *P‐value <0.05

Estimated elastase concentrations by study. Oxidised regenerated cellulose (ORC)/collagen group is represented by black bars and the control group is represented by white bars. *P‐value <0.05

Plasmin concentrations

Three studies reported average elastase levels (Figure 8). , , All three studies reported reduced levels of plasmin in ORC/collagen group compared with the control group, although it was only significant in Kloeters et al. , , A meta‐analysis could not be performed because of plasmin levels being estimated based on graphical presentations.
FIGURE 8

Estimated plasmin concentrations by study. Oxidised regenerated cellulose (ORC)/collagen group is represented by black bars and the control group is represented by white bars. *P‐value <0.05

Estimated plasmin concentrations by study. Oxidised regenerated cellulose (ORC)/collagen group is represented by black bars and the control group is represented by white bars. *P‐value <0.05

Gelatinase concentrations

Two studies reported gelatinase concentrations between ORC/collagen and control groups (Figure 9). , Ulrich et al reported significantly reduced levels of gelatinase in the ORC/collagen group on day 5, 12, 28, and 42. A meta‐analysis could not be performed because of gelatinase levels being estimated based on graphical presentations.
FIGURE 9

Estimated gelatinase concentrations by study. Oxidised regenerated cellulose (ORC)/collagen group is represented by black bars and the control group is represented by white bars. *P‐value <0.05

Estimated gelatinase concentrations by study. Oxidised regenerated cellulose (ORC)/collagen group is represented by black bars and the control group is represented by white bars. *P‐value <0.05

Adverse events

Eight studies reported adverse events. , , , , , , , Adverse events were reported in 87 (7.1%) ORC/collagen group patients and 79 (17.9%) control group patients. Adverse events included pain, infection, allergic reaction, and unspecified type (Table 3). Serious adverse events were reported in 25 (2.0%) ORC/collagen group patients and 35 (7.9%) control patients. Death was reported in two ORC/collagen patients and six control patients, although this was not related to treatment (Table 3).
TABLE 3

Adverse events reported from studies included in the meta‐analysis

Collagen/ORC N = 1224Control N = 443
Number of subjects experiencing an AE87 (7.1%)79 (17.8%)
Number of AEs occurring by type a
Allergic reaction5 (0.4%)5 (1.1%)
Erythema2 (0.16%)3 (0.68%)
Excessive exudate3 (0.24%)4 (0.90%)
Hyper granulation1 (0.08%)4 (0.90%)
Infection14 (1.1%)12 (2.7%)
Inflammation2 (0.16%)7 (1.6%)
Itching/pruritus3 (0.24%)0
Pain18 (1.5%)7 (1.6%)
Perilesional skin irritation8 (0.65%)7 (1.6%)
Unspecified AE type44 (3.6%)49 (11.1%)
Serious AE25 (2.0%)35 (7.9%)
Death b 2 (0.16%)6 (1.4%)
Unspecified23 (1.9%)29 (6.5%)

Abbreviation: AE, adverse event; ORC, oxidised regenerated cellulose.

Patients may experience more than one event.

Death was not related to treatment.

Adverse events reported from studies included in the meta‐analysis Abbreviation: AE, adverse event; ORC, oxidised regenerated cellulose. Patients may experience more than one event. Death was not related to treatment.

DISCUSSION

Chronic and complex wounds can be difficult to heal and may require the use of advanced wound dressings. With the large number of advanced wound dressing options available, a comprehensive assessment of available published literature is warranted to evaluate the performance of these dressings. This systematic literature review and meta‐analysis evaluated wound area reduction, percent area reduction, wound closure rates, and concentrations of MMP‐2, elastase, plasmin, and gelatinase in ORC/collagen dressings compared with standard dressings in patients with all wound types. The literature review identified 20 comparative studies for analysis. The patient populations examined displayed patient risk factors for impaired wound healing, which was representative of the typical patient with chronic or complex wounds. Additionally, the most commonly reported wound types (diabetic foot ulcers and venous leg ulcers) are among the chronic wounds with the highest incidence rates globally. Thus, our results favouring ORC/collagen over standard dressings may be expected in similar, real‐world patient populations. Differences in wound closure rates and wound area reduction were examined between ORC/collagen and standard dressings. Individual studies reported significantly higher rates of wound closure and percentage of wound area reduction in wounds receiving ORC/collagen dressings. , , , , , , These results were mirrored in the meta‐analyses providing strong evidence for ORC/collagen dressing use resulting in improved wound closure and wound area reduction rates. The effect of ORC/collagen dressings on wound bed protease concentrations was inconclusive. While several studies reported reductions in the concentrations of MMP‐2, plasmin, elastase, and gelatinase in the wounds receiving ORC/collagen dressings, , , , , concentration unit and time point differences made it difficult to accurately assess these outcomes. However, the Kloeters et al, Smeets et al, and Ulrich et al studies did report significantly reduced protease concentrations in wounds receiving ORC/collagen dressings indicating that these dressings may alter the wound environment to promote healing. , , Eight studies reported on adverse events with the most commonly reported being pain and infection for both the ORC/collagen dressing and standard dressing groups. A small number of patient deaths were reported for both groups but were deemed unrelated to treatment by study authors. These results indicate that a similar safety profile exists between ORC/collagen and standard dressings. Limited reporting prevented assessment of time to complete healing, days of therapy, number of dressing applications, and pain. As such, more data are needed to fully assess the clinical impact of ORC/collagen dressing use for these outcomes.

Limitations

A majority of the available literature for ORC/collagen dressings are small, non‐comparative studies. While larger, randomised controlled studies will be needed to fully assess the potential clinical and health economic benefits of ORC/collagen dressings, this initial meta‐analysis did find significant effects in favour of ORC/collagen dressing that should not be dismissed because of the mix of comparative studies included in the analysis. Twelve studies did not report any patient risk factors for impaired wound healing. Thus, there is a potential for differences in patient populations between the included studies. However, heterogeneity was assessed and found to be 0%, indicating similar study populations across the included publications. To minimise any potential population heterogeneity, all meta‐analyses were performed using the random effects model. Differences in data reporting between the studies contributed to inconclusive results for time to complete healing, days of therapy, number of dressing applications, and patient reported pain. Additionally, several studies did not report standard deviations for percentage of area reduction, rendering the treatment effect of that outcome less precise. There is always the risk for selection bias when a meta‐analysis is performed. However, the authors followed a well‐defined systematic literature search protocol to help minimise this potential bias. A funnel plot of the studies that reported wound closure odds ratios indicated a minimal risk of publication bias.

CONCLUSIONS

In these meta‐analyses, ORC/collagen dressing use was associated with increased wound closure rates and wound area reduction. More high evidence level studies are needed to fully assess the potential clinical and health economics benefits of ORC/collagen dressings.

ACKNOWLEDGEMENT

The authors thank Ricardo Martinez (3M) for assistance with study development anddesign.

CONFLICT OF INTEREST

S. A. Chowdhry is a consultant for 3M. Y. Nieves‐Malloure, M. Camardo, J. M. Robertson, and J. Keys are employees of 3M.
  27 in total

1.  Expression of matrix-metalloproteases in the fluid of chronic diabetic foot wounds treated with a protease absorbent dressing.

Authors:  M Motzkau; J Tautenhahn; H Lehnert; R Lobmann
Journal:  Exp Clin Endocrinol Diabetes       Date:  2010-10-28       Impact factor: 2.949

2.  Randomized controlled trial on collagen/oxidized regenerated cellulose/silver treatment.

Authors:  Finn Gottrup; Breda Mary Cullen; Tonny Karlsmark; Morten Bischoff-Mikkelsen; Lorraine Nisbet; Molly Camilla Gibson
Journal:  Wound Repair Regen       Date:  2013-02-25       Impact factor: 3.617

3.  Prevalence of chronic wounds in the general population: systematic review and meta-analysis of observational studies.

Authors:  Laura Martinengo; Maja Olsson; Ram Bajpai; Michael Soljak; Zee Upton; Artur Schmidtchen; Josip Car; Krister Järbrink
Journal:  Ann Epidemiol       Date:  2018-11-12       Impact factor: 3.797

4.  Prospective and randomised evaluation of the protease-modulating effect of oxidised regenerated cellulose/collagen matrix treatment in pressure sore ulcers.

Authors:  Oliver Kloeters; Frank Unglaub; Erik de Laat; Marjolijn van Abeelen; Dietmar Ulrich
Journal:  Int Wound J       Date:  2015-05-23       Impact factor: 3.315

5.  The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration.

Authors:  Alessandro Liberati; Douglas G Altman; Jennifer Tetzlaff; Cynthia Mulrow; Peter C Gøtzsche; John P A Ioannidis; Mike Clarke; P J Devereaux; Jos Kleijnen; David Moher
Journal:  PLoS Med       Date:  2009-07-21       Impact factor: 11.069

6.  Use of Oxidized Regenerated Cellulose (ORC)/Collagen/Silver-ORC Dressings Alone or Subsequent to Advanced Wound Therapies in Complex Wounds.

Authors:  Robert J Klein
Journal:  Wounds       Date:  2020-02       Impact factor: 1.546

7.  Evaluation of the nano-oligosaccharide factor lipido-colloid matrix in the local management of venous leg ulcers: results of a randomised, controlled trial.

Authors:  Jean-Luc Schmutz; Sylvie Meaume; Ségolène Fays; Zohva Ourabah; Bernard Guillot; Valéne Thirion; Mark Collier; Simon Barrett; J Smith; Serge Bohbot; Anne Dompmartin
Journal:  Int Wound J       Date:  2008-06       Impact factor: 3.315

8.  Effect of oxidised regenerated cellulose/collagen matrix on proteases in wound exudate of patients with chronic venous ulceration.

Authors:  Ralf Smeets; Dietmar Ulrich; Frank Unglaub; Michael Wöltje; Norbert Pallua
Journal:  Int Wound J       Date:  2008-06       Impact factor: 3.315

Review 9.  Clinical Impact Upon Wound Healing and Inflammation in Moist, Wet, and Dry Environments.

Authors:  Johan P E Junker; Rami A Kamel; E J Caterson; Elof Eriksson
Journal:  Adv Wound Care (New Rochelle)       Date:  2013-09       Impact factor: 4.730

10.  Use of oxidised regenerated cellulose/collagen dressings versus standard of care over multiple wound types: A systematic review and meta-analysis.

Authors:  Saeed A Chowdhry; Yeni Nieves-Malloure; Mark Camardo; Julie M Robertson; Joshua Keys
Journal:  Int Wound J       Date:  2021-06-11       Impact factor: 3.315

View more
  2 in total

Review 1.  Novel Technologies in Chronic Wound Care.

Authors:  Yehiel Hayun; Dafna Shilo Yaacobi; Tal Shachar; Moti Harats; Andrew E Grush; Asaf Olshinka
Journal:  Semin Plast Surg       Date:  2022-06-08       Impact factor: 2.195

2.  Use of oxidised regenerated cellulose/collagen dressings versus standard of care over multiple wound types: A systematic review and meta-analysis.

Authors:  Saeed A Chowdhry; Yeni Nieves-Malloure; Mark Camardo; Julie M Robertson; Joshua Keys
Journal:  Int Wound J       Date:  2021-06-11       Impact factor: 3.315

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.